Robert Floyd
CryoCath Technologies
CYT-T
HOLD
Dec 17, 2004
Recently did a financing which is typical for a lot of biotech companies. Their research is very interesting. Trying to increase their marketing internationally.
Using freezing instead of heat to treat injuries to the heart will be the big driver next year. Good technology that is being accepted. Long term should be good, but short term would be concerned about general market risk.
Just did a financing and the stock can't seem to get beyond the financing price. Unfortunately had to raise cash to get to the next level. Likes the product and the management team. Longer term, it's a good keeper, but doesn't expect a whole lot in the short term. Their US revenues have to ramp up before the market gets excited. Selling his position.
As a medical device company its got its risks. The market they are in is not fully developed, so they need to clear the FDA hurdles, develop a market and hit their milestones. Arctic Circler(R) should be a very big piece of that. Expects to have some very good news in 05/06 on this.
Treats atrial fibrillation (irregular heartbeat). This is a large coming market in cardiac area that is unsolved. The clinical trials they are doing in the US and Europe are indicating that the doctors are really adopting the product. Will probably be the leading therapy in this area. Expecting a takeout, especially if they get FDA approval.
Your Watchlist
Add stocks to watchlist to monitor them daily and get important alerts.